Executive Summary
HHS data reveals $698.6M in major contracts to Carahsoft ($465M obligation, $2.07B potential) for CMS income verification software and Leidos ($233.6M fully obligated) for NIH COVID-19 R&D, both bullish with $493.5M (71%) already outlayed for multi-year revenue through 2029. These awards underscore sustained HHS demand for digital verification tools and biomed R&D amid full/open competition.
Investors gain clear long-term visibility, prioritizing Carahsoft's massive option upside.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All HHS Contracts digest from March 27, 2026.
Investment Signals (2)
- HHS locks in $700M+ govtech and biomed revenue (HIGH)▲
Carahsoft and Leidos secure $698.6M obligations (71% outlayed) via full/open competition, providing low-risk backlog through 2028-2029.
- Carahsoft CSI contract offers 4.4x obligation upside (HIGH)▲
CMS software deal has $465M obligated but $2.07B total potential via options, with $337M already funded signaling execution momentum.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Firm fixed-price (Carahsoft) risks margin squeeze if costs overrun; cost-plus (Leidos) stable but subawards ($8.9M) dilute retention.
- Market [HIGH RISK]▼
Options ($1.6B for Carahsoft) and 3-9 year horizons expose to HHS budget shifts or early termination.
Opportunities (2)
- ◆
$128M Carahsoft + $77M Leidos remaining outlays provide near-term cash flow catalysts.
- ◆
Carahsoft options unlock $1.6B expansion in CMS software; Leidos full obligation ensures R&D stability to 2029.
Sector Themes (1)
- ◆
Full/open awards to non-SB firms signal demand for NAICS 511210 software (Carahsoft) and 541715 biomed R&D (Leidos), with $700M scale.
Watch List (2)
- 👁
{"entity"=>"Carahsoft Technology Corp", "reason"=>"$2.07B ceiling with $1.6B options dominates period value", "trigger"=>"option exercises >$500M or outlays hitting $400M"}
- 👁
{"entity"=>"Leidos Holdings Inc", "reason"=>"Full $234M NIH obligation to 2029 offers backlog stability amid COVID R&D spend", "trigger"=>"outlays surpassing $200M or subaward expansions"}
Get daily alerts with 2 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 2 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All HHS Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals